The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://susanobvu796836.wikiannouncement.com/9516485/glp_3_receptor_agonists_retatrutide_trizepatide